Sanofi: positive opinion from CHMP in dermatitis
This opinion is based on data from the Phase III trial, which showed that Dupixent improved skin healing, reduced overall disease severity and improved health-related quality of life, in children aged between six months and five years.
In Europe, around 80,000 children in this age group suffering from this disease are candidates for systemic treatment. If approved, Dupixent will be the first and only targeted drug available in the EU for the treatment of these young children.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction